Fluoroquinolone antibiotics: Adverse effects and safety profiles

Infectious Diseases in Clinical Practice

Volumn 8, Issue 9, 1999, Pages 421-428

  Dembry, Louise M ^a,b   Farrington, Jane M ^a   Andriole, Vincent T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; WARFARIN;

ANTIBIOTIC THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; NEUROTOXICITY; PHOTOTOXICITY; SHORT SURVEY; SKIN MANIFESTATION; TERATOGENICITY;

EID: 0032755886     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199912000-00008     Document Type: Short Survey

References (38)

1. Andriole VT. Quinolones. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. 2nd ed. Philadelphia: W.B. Saunders; 1998. p. 275-89.
2. Grayson ML. Ciprofloxacin. In: Kucers A, Crowe S, Grayson ML, et al., editors. The use of antibiotics. 5th ed. Oxford, UK: Butterworth-Heinemann; 1997. p. 981-1060.
3. Stahlmann R, Lode H. Safety overview: toxicity, adverse effects, and drug interactions. In: Andriole VT, editor. The quinolones. 2nd ed. London: Academic Press; 1998. p. 370-417.
4. Stahlmann R, Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother 1997;40 Suppl A:83-92.
5. Jungst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance. Drugs 1987;34 Suppl 1:144-9.
6. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994;18: 946-50.
7. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995;13:343-58.
8. Bruch K, Blomer R. Efficacy and safety of ofloxacin in elderly patients. Int J Clin Pharmacol Res 1987;7:195-8.
9. Williams DJ, Hopkins S. Safety and tolerability of intravenous to oral treatment and single dose intravenous or oral prophylaxis with trovafloxacin. Am J Surg 1998;176 Suppl 6A:74S-79S.
10. Andriole VT. Quinolones. In: Andriole VT, editor. Current infectious disease drugs. Philadelphia: Current Medicine, Princeton Academic Press, Inc.; 1996. p.148-64.
11. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
12. Lode H. Safety of the fluoroquinolones. Infect Med 1998;15 Suppl D:28-33.
13. Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health Syst Pharm 1997;54:2569-84.
14. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 1990;26 Suppl B:219-25.
15. Ball P. The quinolones: history and overview. In: Andriole VT, editor. The quinolones. 2nd ed. London: Academic Press; 1998. p. 1-28.
16. Goldstein EJC. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin Infect Dis 1996;23 Suppl:S25-S30.
17. Teng R, Dogolo LC, Willavize SA, et al. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother 1997;39 Suppl B:87-92.
18. Ferguson J, Dawe R. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. J Antimicrob Chemother 1997;40 Suppl A:93-8.
19. Mayne JT, Johnson NJ, Kluwe WM, et al. A study of the phototoxic potential of trovafloxacin in BALB/c mice. J Antimicrob Chemother 1997;39 Suppl B:67-73.
20. Takayama S, Hirohashi M, Kato M, et al. Toxicity of quinolone antibacterial agents. J Toxicol Environ Health 1995;45:1-45.
21. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
22. Beringer PM, Holtom PD, Rho JP. Comparing the newest fluoroquinolones: levofloxacin and sparfloxacin. Formulary 1997;32:926-43.
23. Burdge DR, Nakielna EM, Rabin HR. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis [letter]. Antimicrob Agents Chemother 1995;39:793.
24. Jensen T, Pedersen SS, Nielson CH, et al. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother 1987;20:585-94.
25. Rubio TT, Shapiro C. Ciprofloxacin in the treatment of pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother 1986;18:147-52.
26. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196-204.
27. Giamarellou H, Kilokuthas E, Petrikkos G, et al. Pharmacokinetics of three newer quinolone in pregnant and lactating women. Am J Med 1989;87 Suppl 5A:49-51.
28. Schaad UB, Wedgewood J. Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 1992; 30:414-6.
29. Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986;32:408-17.
30. Andriole VT. The quinolones. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill-Livingstone; 1989. p. 334-45.
31. Bergan T. Pharmacokinetics of the fluoroquinolones. In: Andriole VT, editor. The quinolones. 2nd ed. London: Academic Press; 1998. p.143-82.
32. Guay DR. Implications of quinolone pharmacokinetic drug interactions. Hosp Pharm 1997;32:677-90.
33. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-19.
34. Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992;14:272-84.
35. Grayson ML. Enoxacin. In: Kucers A, Crowe S, Grayson ML, et al., editors. The use of antibiotics. 5th ed. Oxford, UK: Butterworth-Heinemann; 1997. p.1076-84.
36. Grayson ML. Ofloxacin. In: Kucers A, Crowe S, Grayson ML, et al., editors. The use of antibiotics. 5th ed. Oxford, UK: Butterworth-Heinemann; 1997. p.1111-34.
37. Stuht H, Lode H, Koeppe P, et al. Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother 1995;39:1045-9.
38. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin [letter]. Ann Intern Med 1993; 119:1223.